ArticlePloS one2025
A systematic analysis for disease burden, risk factors, and trend projection of Alzheimer's disease and other dementias in China and globally.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Synthesis of 4-Hydroxyacetophenone-Derived Bis-Schiff Bases as Potent Cholinesterase Inhibitors: In Vitro Evaluation, Molecular Docking, DFT, and ADMET Analysis.Chemistry & biodiversity · 2026Article
- AI-Enabled Modeling for Alzheimer's Disease Risk Prediction and Validation.Revista de neurologia · 2026Article
- Targeting cathepsin B activity by natural inhibitors: a structural dynamics and network pharmacology approach for amyloid-beta dysregulation in Alzheimer's disease.Molecular diversity · 2026Article
- Neurosteroid-Mediated Neuroprotection via mTORC1/AMPK/BDNF Signaling Pathway in Alzheimer's Disease.Molecular neurobiology · 2026Review
- Cardiovascular Disease, Cancer and Dementia in Diabetes: 20-Year Trends Will Necessitate New Treatment Priorities.Journal of diabetes · 2026Article
- Social determinants of health, behavioral factors, and incident dementia: a prospective cohort study.Alzheimer's research & therapy · 2026Article
- Article
- Microbial SCFAs as epigenetic mediators: fine-tuning the gut-brain axis in neurodegenerative disorders.Current research in microbial sciences · 2026Review
- Developing a QSPR model for Alzheimer's drugs using topological indices and M-polynomial: A computational study.Scientific reports · 2025Article
- Article
- Diabetes and Alzheimer's Disease.Journal of diabetes · 2025Article
- Sociodemographic, health behavioral, and disease history risk factors for dementia in older adults: a population-based cross-sectional study in Guangzhou, China.Frontiers in public health · 2025Article
- Incidence trends and age-period-cohort analysis of Alzheimer's disease and other dementias in the world and China from 1990 to 2021: analyses based on the Global Burden of Disease Study 2021.Frontiers in neurology · 2025Article
- Trends and forecasts of the prevalence and mortality of Alzheimer's disease and other dementias in China.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to provide improvement directions for aging societies by analyzing the disease burden, risk factors and trend forecasts of AD and other dementias (ADD) in China and globally from 1990 to 2021.
methodsData sourced from Global Burden of Disease 2021. We extracted indicators of disease burden and risk factors for ADD in people aged 40 years and older, including incidence, prevalence, deaths, disability-adjusted life years, years lived with disability and years of life lost. The annual percent change and average annual percent change over the past 32 years were analyzed by Joinpoint regression. Decomposition analysis was used to clarify the contribution of aging, population and epidemiological change. The directions of deaths and incidence in China and globally were predicted using ARIMA model for the next 15 years.
resultsThe disease burden of ADD in China is heavier than in most countries and regions. By 2021, China's disease burden has increased by three times, while the global disease burden has doubled. Females bear more burden but face lower mortality. Population growth is the main reason for the burden. Smoking, high fasting plasma glucose and high body-mass index are the three major risk factors, among which high fasting plasma glucose occupies a dominant position.
conclusionThe disease burden of ADD in China and globally is increasing daily and will remain high in the future. It is urgent to introduce some effective intervention measures to prevent such diseases as early as possible.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.